A new review article published in the September 2026 issue of Neuroscience & Biobehavioral Reviews examines the emerging roles of breast milk derived exosomes in supporting infant brain development while also exploring their potential applications in addressing brain tumors. Titled Breast Milk Exosomes: Implications for Brain Function and Oncogenesis, the paper is authored by Elisavet Kosma, Dimitrios Vrachas, Panagiotis Rodoglou, Marina Tsinoglou, Varvara Michopoulou, Eleni Papakonstantinou, Dimitrios Vlachakis, Christos Adamopoulos, and Christina Piperi. The full abstract is available at https://www.sciencedirect.com/science/article/abs/pii/S0149763426002861.

Exosomes are nanoscale extracellular vesicles measuring 30 to 150 nanometers in diameter. They originate from cells and appear in numerous bodily fluids. These vesicles feature a lipid bilayer membrane enclosing proteins, nucleic acids including microRNAs, messenger RNAs, and long non-coding RNAs, as well as lipids. Breast milk derived exosomes, often abbreviated as MDEs or BMEs, stand out because they facilitate maternal-infant communication. They carry bioactive molecules that survive the acidic environment of the digestive tract and enter systemic circulation.

Research indicates that breastfeeding supports neurodevelopment, particularly in preterm and low-birthweight infants. Components in breast milk influence brain growth, connectivity, and cognitive outcomes. The review synthesizes evidence showing that MDEs contribute to these effects through molecular signaling, immune modulation, and interactions along the gut-brain axis. Maternal nutrition, lifestyle, and environmental factors shape the cargo of these exosomes, affecting immune maturation, gastrointestinal function, and brain development in the infant.

One key capability of milk-derived exosomes involves crossing the blood-brain barrier. Studies demonstrate that exosomes can traverse this protective interface bidirectionally. Mechanisms include lipid raft-mediated endocytosis, receptor-mediated transcytosis, and macropinocytosis. Surface molecules such as integrins and CD46 participate in uptake by recipient cells. This property positions MDEs as potential mediators of neuroprotection, neuronal differentiation, synaptic plasticity, and regulation of neuroinflammation.

The review details how MDEs may influence neural stem cell function and cognitive processes. Evidence from preclinical models links these vesicles to reduced seizure susceptibility and enhanced myelination. Their cargo includes microRNAs that regulate gene expression related to brain health. In early postnatal life, these signals help shape the developing central nervous system while also supporting the maturation of the infant immune system.

Beyond neurodevelopment, the publication addresses implications for oncogenesis, particularly in brain tumors. Brain tumors present heterogeneity that complicates treatment. Tumor-derived extracellular vesicles can cross the blood-brain barrier and enter circulation, serving as potential biomarkers. Conversely, milk-derived exosomes exhibit properties that could modulate the tumor microenvironment and immune responses. The review highlights their ability to activate apoptotic pathways and promote antitumor immunity in preclinical models.

Photo by Steve A Johnson on Unsplash

MDEs show promise as drug delivery vehicles due to high biocompatibility and low immunogenicity. They can be loaded with therapeutic agents and directed toward brain tumors. Related research has explored loading milk exosomes with compounds such as resveratrol to enhance brain delivery and antiproliferative effects on neuroblastoma and glioblastoma cells. Their stability and capacity to reach hard-to-access sites make them attractive candidates for overcoming limitations of conventional therapies.

Inherent antitumor properties of MDEs stem from their content of lipids, microRNAs, and proteins with anti-inflammatory and pro-apoptotic activities. These vesicles may suppress proliferation of certain cancer cells and enhance immune recognition. The review notes ongoing interest in mammalian milk exosomes for cancer applications, including potential roles in modulating epithelial-to-mesenchymal transition and supporting antitumor immune responses.

Challenges remain before clinical translation. Isolation protocols require refinement for purity, scalability, and consistency. Variability in exosome composition based on maternal factors adds complexity. The authors emphasize the need for standardized methods and further preclinical validation to realize therapeutic potential while ensuring safety.

Future directions include expanded studies on MDEs in diverse populations and integration with emerging technologies for exosome engineering. The review calls for interdisciplinary efforts combining developmental biology, neuroscience, and oncology to advance understanding. Such work could inform strategies for supporting infant brain health and developing novel interventions for central nervous system malignancies.

This publication arrives amid growing academic interest in extracellular vesicles across biomedical fields. University researchers and postdoctoral scholars may find opportunities in exosome-related projects, particularly those bridging nutrition, neurodevelopment, and oncology. The comprehensive synthesis of evidence from multiple databases underscores the value of systematic reviews in guiding future investigations.

Stakeholders including pediatric researchers, neuroscientists, and oncologists can draw actionable insights from the highlighted mechanisms. For instance, understanding how maternal diet influences exosome cargo offers avenues for nutritional interventions during lactation. In oncology contexts, the drug-delivery attributes suggest collaborative projects between materials scientists and clinicians to optimize vesicle-based therapies.

Photo by Google DeepMind on Unsplash

Overall, the review provides a balanced perspective on both the established benefits for brain function and the promising yet preliminary applications in cancer contexts. It positions breast milk exosomes as versatile mediators with implications extending from early life development to potential therapeutic innovation.